Trials / Completed
CompletedNCT00250458
Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Elimination of Migraine-Associated Nausea in Migraine Patients Treated With Rizatriptan Orally Disintegrating Tablet (ODT)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 346 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study to test the effectiveness of a marketed drug in the treatment of migraine-associated nausea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Comparator: Rizatriptan | One dose Rizatriptan 10 mg orally disintegrating tablet / oral lyophilisate to treat one migraine attack. |
| DRUG | Comparator: Placebo | One dose matching placebo to Rizatriptan to treat one migraine attack. |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2006-10-01
- Completion
- 2006-10-01
- First posted
- 2005-11-08
- Last updated
- 2022-02-03
- Results posted
- 2010-06-23
Source: ClinicalTrials.gov record NCT00250458. Inclusion in this directory is not an endorsement.